FDA Downgrades Opioid Oxygen Monitor to Class II
Published Date: 6/30/2026
Rule
Summary
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Class II Reclassification Speeds Access
FDA has classified the monitor for opioid-induced impairment of oxygenation as Class II (special controls). This final order is effective June 30, 2026 (and the classification was applicable on March 31, 2023), and FDA says the change provides reasonable assurance of safety and effectiveness while enhancing patients' access by reducing regulatory burdens.
Easier Route to Market for Makers
Because FDA placed this monitor into Class II via the De Novo process, the device can serve as a predicate for future devices so other sponsors can use the less burdensome 510(k) pathway instead of De Novo or premarket approval. FDA states this will enhance patient access in part by reducing regulatory burdens and could lower costs and delays for companies making these monitors.
Special Controls Require Testing and Documentation
Manufacturers of these monitors must meet detailed special controls, including clinical performance data (accuracy, sensitivity, specificity), software verification and validation with hazard analysis, non-clinical sensor performance testing, usability assessment, biocompatibility, and electromagnetic and safety testing. Compliance with these special controls is required for the device to remain in Class II and avoid automatic placement in Class III.
Labels Must Include Overdose Warnings and Info
Labeling for these monitors must include a summary of clinical validation (including sensitivity, specificity, positive and negative predictive values by subpopulation), principles of sensor operation, information on preventing, recognizing, and treating an overdose, warnings that the device may not distinguish other conditions, warnings against overreliance, and a warning about the need for supervised use with awareness of countermeasures such as naloxone.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16666, Determination That ANSAID (Flurbiprofen) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that ANSAID (flurbiprofen) tablets, 50 milligrams (mg) and 100 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for flurbiprofen tablets, 50 mg and 100 mg, if all other legal and regulatory requirements are met.
2026-16648, Determination That LASIX (Furosemide) Tablets, 20 Milligrams, 40 Milligrams, and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that LASIX (furosemide) tablets, 20 milligrams (mg), 40 mg, and 80 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
2026-16650, Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. PDUFA authorizes FDA to collect user fees to support the process for the review of human drug applications. The current legislative authority for PDUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. Following discussions with the regulated industry and periodic consultations with public stakeholders, the Federal Food, Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the recommendations for the reauthorized program in the Federal Register, hold a meeting at which the public may present its views on such recommendations, and provide for a period of 30 days for the public to provide written comments on such recommendations. FDA will then consider such public views and comments and revise such recommendations, as necessary.
Previous / Next Documents
Previous: 2026-13139, Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
Next: 2026-13153, Magnuson-Stevens Fishery Conservation and Management Act Provisions; Fisheries of the Northeastern United States; Northeast Multispecies Fishery; Amendment 25 (Revised)
Starting June 30, 2026, new rules update how Atlantic cod stocks are managed in the Northeast multispecies fishery. These changes affect both commercial and recreational fishers by setting fresh limits and protections to stop overfishing and help cod populations bounce back. The goal? Keep fishing fun and sustainable while supporting a $40 million industry.